AZILECT is Generally Well Tolerated

  • Regardless of age or concomitant levodopa treatment1,2
  • Cognitive and behavioral adverse events were comparable to placebo, based on UPDRS Part 1 (mentation, behavior, and mood)3
  • AZILECT shown to be selective for MAO-B at recommended doses1
     - No dietary tyramine restriction ordinarily required when AZILECT is taken at recommended doses
Side Effects of Monotherapy
 

Please see important safety information and complete prescribing information. 

Learn more about convenient dosing with AZILECT.

REFERENCES
1. AZILECT Prescribing Information.
2. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson Study Group. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66:1427-1429.
3. Elmer L,  Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006;248(1-2):78-83.


 

 

AZL101023775/101252

 

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s Disease (PD) as initial monotherapy and as adjunct therapy to levodopa.

IMPORTANT SAFETY INFORMATION ABOUT AZILECT

Azilect is contraindicated with meperidine; the analgesics tramadol, methadone, and propoxyphene; the antitussive agent dextromethorphan; as well as St. John’s wort and cyclobenzaprine. Azilect is also contraindicated with other MAOIs.

In general, the combination of Azilect and antidepressants should be avoided. Caution should be used when giving Azilect concurrently with CYP1A2 inhibitors such as ciprofloxacin. Patients with moderate to severe hepatic impairment should not take Azilect. The daily dose of Azilect should not exceed 1 mg because of the risks associated with nonselective inhibition of MAO. PD patients are advised to monitor for melanoma frequently and see a dermatologist on a regular basis.

The most common side effects as monotherapy include: flu syndrome, arthralgia, depression, and dyspepsia; and as adjunct to levodopa therapy include: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.

AZL101023762/101241